Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...

Untitled Document

LexaGene Holdings, Inc. (LXXGF)

A biotechnology company listed on the OTCQB, LexaGene Holdings, Inc. develops instrumentation for pathogen detection. It is developing the LX6, which is the very first fully automated pathogen detection platform that is open-access. This open-access feature will enable end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection. LexaGene Holdings has its corporate headquarters in Beverly, Massachusetts.

Earlier this month, LexaGene announced that it considerably expanded its operations in Massachusetts. The company recently signed a lease for a 17,500-square-foot space, located at 500 Cummings Center, Suite 4550, in Beverly.

LexaGene Holdings is working to change the pathogen detection landscape through providing a customizable sample-to-answer instrument, which is more rapid and sensitive than anything presently available. It is working to transform the way pathogen testing is performed by multi-billion dollar industries. These industries include food safety, veterinary diagnostics, water quality management, aquaculture farming, and more.

LexaGene Holdings has strategic relationships with Boston Engineering – a development partner; as well as the Lawrence Livermore National Laboratory. The company's Microfluidic Technology is open access - users can load standard pathogen specific assays onto the instrument for customized testing.

A feature of this technology is extreme sensitivity. The flow-through instrument processes huge sample volumes to maximize the chances of detecting ultra-rare pathogens. The Microfluidic Technology features low cost per test and it is also user-friendly.

At the end of November 2017, LexaGene announced that it completed the assembly of its prototype for what will be the world's first fully automated, open-access and on-site pathogen detection platform. This technology will be able to screen for up to 22 pathogens at once and deliver results in one hour. The design of the technology is also to be used by people with no knowledge of automated instrumentation, microbiology, or molecular biology.

Recently, LexaGene Holdings announced that the TSX Venture Exchange ranked the company in its 2018 TSX Venture 50. This is a yearly ranking of top performing companies on the Exchange.

Dr. Jack Regan, LexaGene Holdings' Chief Executive Officer, said, "Being recognized as a top 50 company for the Exchange reflects the rapid growth we've experienced in 2017 and great support from the investment community. Following our recent completion of the assembly of our prototype for what will be the world's first fully automated, open-access and on-site pathogen detection platform, LexaGene is poised to make a powerful impact for industries interested in pathogen detection – from food safety to veterinary diagnostics."




The QualityStocks

Read the articles covering the biggest movers in the markets today.



Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.


The QualityStocks Daily

Go back to see our previous newsletters and find out what you might have missed.